Can Dash Bio’s $30m automation bet break one of drug development’s slowest bottlenecks?
Dash Bio’s $30 million Series A backs automated bioanalysis expansion, but validation, scale and sponsor adoption will determine its impact.
Medical Devices & Diagnostics